See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.Large accelerated fileroAccelerated fileroNon-accelerated Filerx(Do not check if a smaller reporting company)Smaller reporting companyoThe Registrant is an “emerging growth company,” as defined in Section 2(a) of the Securities Act. This registration statement complies with the requirements that apply to an issuer that is an emerging growth company.CALCULATION OF REGISTRATION FEETitle of each class of securities to be registeredAmount to beRegistered(1)ProposedMaximumOffering PricePer Share(2)ProposedMaximumAggregateOfferingPrice(2)Amount ofRegistration Fee(3)Common Stock, par value $0.001 per share1,725,000$69.14$119,266,500$15,361.53(1)Includes shares that the underwriter has the option to purchase.(2)Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended, on the basis of the average of the high and low selling prices of the Registrant's Common Stock reported on the NASDAQ Global Market as of a date (October 4, 2013) within five business days prior to filing this Registration Statement.(3)The Registrant previously paid $14,812 in connection with the initial filing of this Registration Statement.The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to such Section 8(a), may determine.TABLE OF CONTENTSThe information in this preliminary prospectus is not complete and may be changed.
In particular, you should consider the following risks, which are discussed more fully in the section entitled “Risk Factors” in this prospectus and in our Annual Report on Form 10-K for the year ended December 31, 2012 and our subsequent periodic and current reports filed with the Securities and Exchange Commission incorporated by reference herein.•we have never been profitable, have no products approved for commercial sale and to date have not generated any revenue from product sales;•we will require substantial additional funding to complete the development and commercialization of OCA and to continue to advance the development of our other product candidates, and such funding may not be available on acceptable terms or at all;•OCA and/or our other product candidates may not receive regulatory approval in a timely manner or at all;•the FDA may not agree to our proposed surrogate endpoint for accelerated approval of OCA for the treatment of PBC, in which case we would need to complete an additional Phase 3 trial in order to seek approval in the United States instead of being able to seek approval based on a clinical outcomes trial to be completed after accelerated approval;•we may be subject to delays in our clinical trials, which could result in increased costs and delays or limit our ability to obtain regulatory approval for our product candidates;•because the results of earlier studies and clinical trials of our product candidates may not be predictive of future clinical trial results, our product candidates may not have favorable results in future clinical trials, which would delay or limit their future development;•we are in a highly competitive industry and face competition from existing and new treatments that may be more effective and less costly than our products;•we have never commercialized any of our product candidates and our products, even if approved, may not be accepted by healthcare providers or healthcare payors;•the failure of our collaborators to perform their obligations under our collaboration agreements may delay or otherwise harm the development and commercialization of our product candidates; and•we may be unable to maintain and protect our intellectual property assets, which could impair the advancement of our pipeline and commercial opportunities.5TABLE OF CONTENTSImplications of Being an Emerging Growth CompanyWe qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company, we currently take advantage of reduced disclosure and other requirements that are otherwise applicable generally to public companies.
This offering will have no effect on the number of shares of our common stock outstanding.Option to purchase additional sharesThe selling stockholders have granted the underwriter an option for a period of up to 30 days to purchase up to 225,000 additional shares of common stock at the offering price.Use of proceedsWe will not receive any proceeds from the sale of common stock by the selling stockholders in this offering.Risk factorsYou should read the “Risk Factors” section of this prospectus, our Annual Report on Form 10-K for the year ended December 31, 2012 and our subsequent periodic and current reports filed with the Securities and Exchange Commission incorporated by reference herein for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.Nasdaq Global Market symbolICPTThe number of shares of common stock to be outstanding after this offering is based on an aggregate of 19,261,799 shares outstanding as of September 16, 2013.
For more details on how you can obtain the documents incorporated by reference in this prospectus, see “Where You Can Find More Information” and “Incorporation of Documents by Reference.”Year Ended December 31,Six Months EndedJune 30,Period From September 4, 2002 (Inception) Through June 30, 201320102011201220122013(in thousands, except share and per share amounts)(unaudited)(unaudited)Statement of Operations Data:Licensing revenue$—$1,805$2,446$1,518$811$5,062Costs and expenses:Research and development12,71011,42616,1838,0789,96681,400General and administrative3,6444,2095,1772,0035,28734,885Total operating expenses16,35415,63521,36010,08115,253116,286Other income (expense):Revaluation of warrants6721,045(24,626)979(9,255)(32,330)Other income (expense), net59448(104)(182)101,6831,2661,093(24,730)797(9,245)(30,647)Net loss(15,088)(12,737)(43,643)(7,766)(23,687)(141,870)Dividends on preferred stock, not declared(2,901)(3,000)(2,630)(1,500)—(10,944)Net loss attributable to common stockholders$(17,989)$(15,737)$(46,273)$(9,266)$(23,687)$(152,815)Net loss per common share, basic and diluted:$(5.40)$(4.73)$(7.36)$(2.78)$(1.41)Weighted average shares outstanding, basic and diluted:3,329,6663,329,6666,283,2383,329,26616,765,46415TABLE OF CONTENTSDecember 31,June 30,2013201020112012(in thousands)(unaudited)Balance Sheet Data:Cash, cash equivalents and investment securities$15,424$17,707$110,194$161,799Total assets17,11819,470112,179163,869Working capital13,89014,87298,814156,299Accounts payable, accrued expenses and otherliabilities1,5871,5043,7463,672Warrant liability, total6,8815,83630,35932,574Deferred revenue, total—14,60812,16211,351Common and preferred stock31311719Additional paid-in capital70,26872,134184,100258,233Accumulated deficit during development stage(61,803)(74,540)(118,183)(141,870)Total stockholder's equity (deficit)8,318(2,560)65,912116,27216TABLE OF CONTENTSPRINCIPAL AND SELLING STOCKHOLDERSThe following table sets forth certain information regarding the beneficial ownership of our common stock as of September 16, 2013, on an actual basis and as adjusted to reflect the sale of our common stock by the selling stockholders in this offering, by:•our named executive officers;•each of our directors;•all of our current directors and executive officers as a group;•each stockholder known by us to own beneficially more than five percent of our common stock; and•each of the selling stockholders.Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and includes voting or investment power with respect to the securities.